Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search


Phylogica Solidifies Intellectual Property Suite

Phylogica Solidifies International Intellectual Property Suite Through Key US Patent.

Phylogica Ltd today received formal Notice of Allowance from the US Patent and Trademark Office (USPTO) for its pending application entitled: "Isolating Biological Modulators from Biodiverse Gene Fragment Libraries - USPTO application 09:568229". This patent secures the second "pillar" of Phylogica's international intellectual property (IP) suite in the key US market. Phylogica's IP covers the "Phylomer" libraries as well as the concept of using protein parts from sequenced genomes, other than those of a target protein, to block the interaction of that target protein.

Phylogica already has patents covering the method of screening for Phylomers in Australia and the US. The patent to be granted is one of eight patent families being maintained by Phylogica and will be its fifth fully granted patent.

According to Phylogica's Scientific Director Dr Paul Watt, this is a reflection of the maturity of Phylogica's patent portfolio. "We're delighted to have secured claims, in one of the toughest jurisdictions in the world and our largest market, covering the two key components of our fundamental enabling technology platform." Dr Watt said.

"This is a key milestone for Phylogica" said Dr Stewart Washer, CEO. "Phylogica's proprietary 'Phylomer' libraries currently contain millions of different parts of proteins. This and further extensions to the library are covered by this patent. Overall it solidifies the position of Phylogica as a leader in the field of peptide therapies and the large markets associated with this drug class. " said Dr Washer.

"Phylomers", which are parts of proteins from Phylogica's proprietary drug discovery libraries, have the potential to block disease protein interactions, providing an alternative to current protein blocking drugs such as antibodies as well as extending the range of protein targets that can be addressed beyond those available to current therapeutic techniques. Phylogica already has a proprietary lead drug candidate product pipeline in this area that is being developed.

About Phylogica

Phylogica ( was founded and incorporated in 2001 to commercialise its proprietary drug discovery technologies developed over six years through a collaboration between the Telethon Institute for Child Health Research in Perth ( and the Fox Chase Cancer Center ( in Philadelphia, United States. The founding research institutes have assigned their rights to the technologies into Phylogica in exchange for shareholdings in the Company. Phylogica Ltd is now a public company traded on the Australian Stock Exchange (ASX:PYC)

About Phylomers

Phylomers(r) are stable fragments of naturally-occurring proteins with the ability to bind tightly to target proteins and inactivate them as a result. Phylomers(r) can be selected for activity against specific disease-target proteins.

Phylogica's proprietary Phylomer(r) Libraries, consist of collections of millions of Phylomers(r). The libraries represent a source of drug leads which double as agents for the validation of potential new targets.


© Scoop Media

Business Headlines | Sci-Tech Headlines


I Sing The Highway Electric: Charge Net NZ To Connect New Zealand

BMW is turning Middle Earth electric after today announcing a substantial contribution to the charging network Charge Net NZ. This landmark partnership will enable Kiwis to drive their electric vehicles (EVs) right across New Zealand through the installation of a fast charging highway stretching from Kaitaia to Invercargill. More>>


Watch This Space: Mahia Rocket Lab Launch Site Officially Opened

Economic Development Minster Steven Joyce today opened New Zealand’s first orbital launch site, Rocket Lab Launch Complex 1, on the Mahia Peninsula on the North Island’s east coast. More>>


Marketing Rocks!
Ig Nobel Award Winners Assess The Personality Of Rocks

A Massey University marketing lecturer has received the 2016 Ig Nobel Prize for economics for a research project that asked university students to describe the “brand personalities” of three rocks. More>>


Nurofen Promotion: Reckitt Benckiser To Plead Guilty To Misleading Ads

Reckitt Benckiser (New Zealand) intends to plead guilty to charges of misleading consumers over the way it promoted a range of Nurofen products, the Commerce Commission says. More>>


Half A Billion Accounts, Including Xtra: Yahoo Confirms Huge Data Breach

The account information may have included names, email addresses, telephone numbers, dates of birth, hashed passwords (the vast majority with bcrypt) and, in some cases, encrypted or unencrypted security questions and answers. More>>


Rural Branches: Westpac To Close 19 Branches, ANZ Looks At 7

Westpac confirms it will close nineteen branches across the country; ANZ closes its Ngaruawahia branch and is consulting on plans to close six more branches; The bank workers union says many of its members are nervous about their futures and asking ... More>>

Interest Rates: RBNZ's Wheeler Keeps OCR At 2%

Reserve Bank governor Graeme Wheeler kept the official cash rate at 2 percent and said more easing will be needed to get inflation back within the target band. More>>


Get More From Scoop

Search Scoop  
Powered by Vodafone
NZ independent news